biostudies-literatureAlexander JLNIHR Exeter Clinical Research FacilityMedical Research CouncilNational Institute for Health Research (NIHR)NIHR Imperial Biomedical Research CentreImperial College LondonNational Institute for Health and Care ResearchImperial College Healthcare NHS TrustBiotechnology and Biological Sciences Research Council104430https://www.ebi.ac.uk/biostudies/studies/S-EPMC9831064biostudies-literatureUnknown88<h4>Background</h4>Patients with inflammatory bowel disease (IBD) treated with anti-TNF therapy exhibit attenuated humoral immune responses to vaccination against SARS-CoV-2. The gut microbiota and its functional metabolic output, which are perturbed in IBD, play an important role in shaping host immune responses. We explored whether the gut microbiota and metabolome could explain variation in anti-SARS-CoV-2 vaccination responses in immunosuppressed IBD patients.<h4>Methods</h4>Faecal and serum samples were prospectively collected from infliximab-treated patients with IBD in the CLARITY-IBD study undergoing vaccination against SARS-CoV-2. Antibody responses were measured following two doses of either ChAdOx1 nCoV-19 or BNT162b2 vaccine. Patients were classified as having responses above oEBioMedicineThe gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.PMC9831064MC_PC_12025MR/S034919/1CL-2019-21-502BBS/E/T/000PR9819NIHR300543Prabhudev HSaifuddin ALin SAhmad TSebastian STeare JPLiu ZHart AAlexander JLKennedy NAKorcsmaros TSands CLees CWMullish BHPowell NMarchesi JRLewis MDanckert NPGoodhand JROlbei MLIbraheim HTorkizadeh MBlanco JMRoberts LABewshea CMHorneffer-van der Sluis VNice RfalseThe gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.<h4>Background</h4>Patients with inflammatory bowel disease (IBD) treated with anti-TNF therapy exhibit attenuated humoral immune responses to vaccination against SARS-CoV-2. The gut microbiota and its functional metabolic output, which are perturbed in IBD, play an important role in shaping host immune responses. We explored whether the gut microbiota and metabolome could explain variation in anti-SARS-CoV-2 vaccination responses in immunosuppressed IBD patients.<h4>Methods</h4>Faecal and serum samples were prospectively collected from infliximab-treated patients with IBD in the CLARITY-IBD study undergoing vaccination against SARS-CoV-2. Antibody responses were measured following two doses of either ChAdOx1 nCoV-19 or BNT162b2 vaccine. Patients were classified as having responses above o2023-01-01T00:00:00Z2023 Feb2026-05-27T23:13:29.079Z2024-11-07T06:13:52.644ZS-EPMC98310643663456510.1016/j.ebiom.2022.104430